Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers

NCT01425879 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01425879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01425879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
May 31, 2014
Enrollment
8 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma, localized non-resectable adult liver carcinoma, recurrent adult liver carcinoma, recurrent gallbladder carcinoma, stage iv distal bile duct cancer, stage iv gallbladder cancer, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma